TuHURA Biosciences (HURA) Expected to Release Quarterly Earnings on Thursday

TuHURA Biosciences (NASDAQ:HURA) is anticipated to post its results before the market opens on Thursday, March 26th. Analysts expect TuHURA Biosciences to post earnings of ($0.1233) per share for the quarter.

TuHURA Biosciences Stock Performance

Shares of HURA opened at $1.88 on Thursday. The stock has a 50 day moving average price of $1.14 and a 200 day moving average price of $1.69. TuHURA Biosciences has a one year low of $0.41 and a one year high of $4.44. The stock has a market capitalization of $114.15 million, a price-to-earnings ratio of -3.76 and a beta of -0.30.

Institutional Trading of TuHURA Biosciences

Several institutional investors have recently added to or reduced their stakes in HURA. Geode Capital Management LLC boosted its position in shares of TuHURA Biosciences by 111.4% during the second quarter. Geode Capital Management LLC now owns 582,992 shares of the company’s stock worth $1,300,000 after buying an additional 307,260 shares during the period. Deutsche Bank AG raised its holdings in shares of TuHURA Biosciences by 209.8% in the 4th quarter. Deutsche Bank AG now owns 79,816 shares of the company’s stock valued at $61,000 after buying an additional 54,051 shares during the period. New York State Common Retirement Fund purchased a new stake in shares of TuHURA Biosciences in the 2nd quarter valued at $97,000. Goldman Sachs Group Inc. acquired a new position in TuHURA Biosciences during the 4th quarter worth about $30,000. Finally, Marshall Wace LLP acquired a new position in TuHURA Biosciences during the 2nd quarter worth about $79,000. Institutional investors and hedge funds own 0.62% of the company’s stock.

Analyst Upgrades and Downgrades

Several brokerages have issued reports on HURA. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of TuHURA Biosciences in a research note on Thursday, January 22nd. HC Wainwright reissued a “buy” rating and issued a $10.00 price target on shares of TuHURA Biosciences in a research note on Tuesday, February 3rd. Finally, Wall Street Zen upgraded shares of TuHURA Biosciences from a “sell” rating to a “hold” rating in a research report on Saturday, March 14th. One equities research analyst has rated the stock with a Strong Buy rating, two have issued a Buy rating and one has given a Sell rating to the stock. According to MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average price target of $9.00.

About TuHURA Biosciences

TuHURA Biosciences is a clinical‐stage biotechnology company focused on the discovery and development of novel therapeutics using high‐dimensional proteomics. The company’s core mission is to translate complex protein signatures into actionable drug targets across a range of disease areas. By integrating proteomic data with advanced computational analytics, TuHURA aims to bridge the gap between molecular disease understanding and the development of first‐in‐class therapies.

At the heart of TuHURA’s approach is its proprietary platform, which leverages multiplexed protein profiling to generate rich phenotypic maps of disease states.